Bayer AG NA Asset Resilience Ratio
Bayer AG NA asset resilience ratio. Bayer AG NA (BAYN) has an Asset Resilience Ratio of 7.10% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bayer AG NA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bayer AG NA (2000–2025)
Asset resilience ratio of Bayer AG NA from 2000 to 2025. This chart shows how Bayer AG NA's Asset Resilience Ratio has changed over time. Read how much debt does Bayer AG NA carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bayer AG NA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Bayer AG NA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.67 Billion | 6.03% |
| Short-term Investments | €1.19 Billion | 1.07% |
| Total Liquid Assets | €7.86 Billion | 7.10% |
Asset Resilience Insights
- Limited Liquidity: Bayer AG NA maintains only 7.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bayer AG NA Industry Peers by Asset Resilience Ratio
Compare Bayer AG NA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Bayer AG NA Asset Resilience Ratio by Year (2000–2025)
Bayer AG NA asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Bayer AG NA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.10% | €7.86 Billion ≈ $9.18 Billion |
€110.61 Billion ≈ $129.31 Billion |
-0.19pp |
| 2024-12-31 | 7.30% | €8.09 Billion ≈ $9.45 Billion |
€110.85 Billion ≈ $129.60 Billion |
-1.81pp |
| 2023-12-31 | 9.11% | €10.59 Billion ≈ $12.38 Billion |
€116.26 Billion ≈ $135.92 Billion |
+0.98pp |
| 2022-12-31 | 8.13% | €10.15 Billion ≈ $11.87 Billion |
€124.88 Billion ≈ $145.99 Billion |
+1.69pp |
| 2021-12-31 | 6.44% | €7.74 Billion ≈ $9.05 Billion |
€120.24 Billion ≈ $140.57 Billion |
-3.72pp |
| 2020-12-31 | 10.15% | €11.88 Billion ≈ $13.89 Billion |
€117.05 Billion ≈ $136.84 Billion |
+5.87pp |
| 2019-12-31 | 4.28% | €5.40 Billion ≈ $6.32 Billion |
€126.26 Billion ≈ $147.61 Billion |
+0.85pp |
| 2018-12-31 | 3.43% | €4.34 Billion ≈ $5.07 Billion |
€126.28 Billion ≈ $147.64 Billion |
-8.68pp |
| 2017-12-31 | 12.12% | €9.10 Billion ≈ $10.64 Billion |
€75.09 Billion ≈ $87.78 Billion |
+5.52pp |
| 2016-12-31 | 6.60% | €5.42 Billion ≈ $6.34 Billion |
€82.24 Billion ≈ $96.14 Billion |
+6.23pp |
| 2015-12-31 | 0.37% | €272.00 Million ≈ $318.00 Million |
€73.92 Billion ≈ $86.42 Billion |
+0.15pp |
| 2014-12-31 | 0.22% | €154.00 Million ≈ $180.04 Million |
€70.23 Billion ≈ $82.11 Billion |
-0.05pp |
| 2013-12-31 | 0.27% | €138.00 Million ≈ $161.34 Million |
€51.32 Billion ≈ $59.99 Billion |
-0.39pp |
| 2012-12-31 | 0.66% | €339.00 Million ≈ $396.33 Million |
€51.34 Billion ≈ $60.02 Billion |
-4.62pp |
| 2011-12-31 | 5.28% | €2.78 Billion ≈ $3.25 Billion |
€52.77 Billion ≈ $61.69 Billion |
+3.32pp |
| 2010-12-31 | 1.96% | €1.01 Billion ≈ $1.18 Billion |
€51.51 Billion ≈ $60.22 Billion |
+1.24pp |
| 2009-12-31 | 0.72% | €367.00 Million ≈ $429.06 Million |
€51.04 Billion ≈ $59.67 Billion |
-0.49pp |
| 2008-12-31 | 1.21% | €634.00 Million ≈ $741.21 Million |
€52.51 Billion ≈ $61.39 Billion |
+0.56pp |
| 2007-12-31 | 0.65% | €335.00 Million ≈ $391.65 Million |
€51.38 Billion ≈ $60.07 Billion |
+0.53pp |
| 2006-12-31 | 0.12% | €69.71 Million ≈ $81.50 Million |
€55.89 Billion ≈ $65.34 Billion |
-0.51pp |
| 2005-12-31 | 0.64% | €233.03 Million ≈ $272.44 Million |
€36.69 Billion ≈ $42.90 Billion |
+0.56pp |
| 2004-12-31 | 0.08% | €28.77 Million ≈ $33.63 Million |
€37.78 Billion ≈ $44.16 Billion |
-0.27pp |
| 2003-12-31 | 0.34% | €128.63 Million ≈ $150.39 Million |
€37.38 Billion ≈ $43.70 Billion |
+0.28pp |
| 2002-12-31 | 0.07% | €28.59 Million ≈ $33.42 Million |
€41.73 Billion ≈ $48.79 Billion |
-0.07pp |
| 2001-12-31 | 0.14% | €51.70 Million ≈ $60.44 Million |
€37.10 Billion ≈ $43.38 Billion |
-0.45pp |
| 2000-12-31 | 0.59% | €214.01 Million ≈ $250.20 Million |
€36.55 Billion ≈ $42.73 Billion |
-- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more